AbCellera Stock Soars 30% After Menopause Drug ABCL635 Hits Phase 2 Success In Hot Flash Trial Results

VANCOUVER, British Columbia — Shares of AbCellera Biologics Inc. surged more than 30% Monday after the clinical-stage biotechnology company announced positive top-line results from a Phase 2 trial of its experimental menopause drug, ABCL635, sending the stock to its highest level in months.

The stock closed up 30.32% at $9.03, with volume of more than 12.7 million shares, well above its three-month average of roughly 7.2 million shares, lifting the company's market capitalization to about $2.76 billion. The rally came after AbCellera said before the market opened that its Phase 2 study evaluating ABCL635 for moderate-to-severe vasomotor symptoms, more commonly known as hot flashes, had met its primary efficacy endpoints.

ABCL635 is an investigational antibody designed to target NK3R, a receptor found on a specific set of neurons in the hypothalamus that plays a role in regulating body temperature. The drug is being developed as a non-hormonal, long-acting, subcutaneous treatment, an approach the company has positioned as a potential alternative to existing hormone-based therapies for menopause symptoms.

The randomized, double-blind, placebo-controlled trial enrolled 92 postmenopausal women who were experiencing an average of roughly 10 moderate or severe hot flashes per day. Participants were randomly assigned to receive either a single 600-milligram subcutaneous dose of ABCL635 or a placebo. At week four, the treatment group saw hot flash frequency drop by a mean of 8.8 events per day from baseline, compared with a 3.5 event reduction in the placebo group, a placebo-adjusted difference of 5.3 events that was statistically significant. In percentage terms, ABCL635 reduced hot flash frequency by 83% on average, compared with a 33% reduction for placebo.

The drug also showed a significant effect on symptom severity, with treated patients seeing severity scores fall by 1.4 points on average compared with 0.3 points for placebo, and meaningful improvements were observed in patient-reported sleep quality and overall impression of symptom change. AbCellera said the drug was well tolerated over the four-week treatment period, with no serious adverse events, severe adverse events, or discontinuations due to side effects. The most common adverse events among patients receiving the treatment were headache, fatigue and injection site reactions.

Dr. JoAnn V. Pinkerton, a professor of obstetrics and gynecology at the University of Virginia School of Medicine who specializes in women's midlife health, said the four-week data set "a new efficacy benchmark for the reduction of hot flashes both in frequency and severity." She added that if the results are validated in a larger Phase 3 trial, the drug could offer patients a more convenient dosing option with potentially less toxicity than existing treatments.

Sarah Noonberg, AbCellera's chief medical officer, described the results as a milestone both for the company and for women's health more broadly. She said the data show that by targeting the NK3 receptor with an antibody, the company has demonstrated "potential best-in-class vasomotor symptom relief over four weeks with a single subcutaneous dose."

The trial results carry particular significance for AbCellera because ABCL635 represents the company's first internally developed drug candidate to advance into Phase 2 testing, marking a shift for a company that built its early business primarily around providing antibody discovery technology and services to pharmaceutical partners rather than developing its own drugs. Vasomotor symptoms affect an estimated 80% of women during menopause, according to figures cited by the company, with the majority describing their symptoms as moderate to severe. AbCellera estimates roughly 12 million women in the United States experience moderate-to-severe hot flashes, of which more than 6 million seek treatment, underscoring the size of the potential market opportunity if the drug advances successfully through later-stage trials and regulatory review.

Monday's surge builds on a period of already elevated investor interest in AbCellera. The company's shares had climbed more than 136% year-to-date heading into the results, according to recent analysis of the stock's performance, reflecting growing attention to the company's pipeline as it has increasingly emphasized internal drug development alongside its existing antibody discovery partnerships. AbCellera has also struck a series of collaboration deals in recent months, including a multispecific antibody partnership with Vertex Pharmaceuticals and prior agreements with Jazz Pharmaceuticals and AbbVie, deals the company has said brought in more than $110 million in upfront payments combined.

The company reported second-quarter 2026 financial results on August 5, ahead of Monday's trial data, showing revenue of roughly $4.05 million, down sharply from the prior year, alongside a widened net loss of $55.4 million. AbCellera has said it holds approximately $567 million in cash and more than $675 million in total available liquidity, which the company has said supports at least three years of continued investment across its pipeline.

Following Monday's results, AbCellera hosted an investor conference call to discuss the Phase 2 data in greater detail and outline next steps for ABCL635's development, including plans for further validation in a larger Phase 3 trial. Analysts covering the stock had already shown signs of growing optimism ahead of the data release, with several firms raising their price targets on the shares in the days leading up to Monday's announcement.

With ABCL635 emerging as the company's most advanced internally developed program, Monday's results are likely to serve as a key reference point for how investors value AbCellera's broader pipeline going forward, particularly as the company continues to balance its established antibody discovery business against the larger financial risks and potential rewards associated with advancing its own drug candidates through clinical development.